Skip to content
Declared
Official portrait of Aengus Ó Snodaigh
Photo: Houses of the Oireachtas

Politician · TD · 34th Dáil

Aengus Ó Snodaigh

Sinn Féin

Constituency / panel
Dublin South-Central
Membership
2024-11-29 → current
Committees
8 current — Committee on Parliamentary Privileges and Oversight (Dáil Éireann); Committee on Remit Oversight (Dáil Éireann); …

Lobbying returns

Returns filed on the Register of Lobbying, newest first, with the policy area and intended results as the lobbyist published them.

Download CSV 775 rows, with the filters applied
Register of Lobbying2017-06-02

Lobbying return by Skill Set Strategy and Technology Services Ltd.

Agriculture
Intended results

To highlight the major negative impacts for farm incomes, job creation and investment arising from the undierentiated approach the the EU Commission is promoting in its latest policy proposals on crop-based biofuels and to encourage Members of Dail & Seanad Eireann and of the…

Register of Lobbying2017-05-19

Lobbying return by Trócaire

Environment
Intended results

Encouraging TDs to support the Fossil Fuel Divestment Bill

Derived link · Matched by exact company name

Published name "Trócaire" equals CRO name "TROCAIRE" (CRO 661147) after normalising legal forms such as Ltd = Limited. No other CRO company has this name. Names can be shared, so compare the address and dates on the CRO record.

Register of Lobbying2017-05-19

Lobbying return by Dublin Chamber of Commerce

Economic Development and Industry
Intended results

Ensure joined up thinking across the local authorities of County Dublin and Greater Dublin Area.::Development of a long-term strategy for the promotion of the region. Recognition of Dublin's vital role as a driver of national economic growth.::Promote city regions as the drivers…

Register of Lobbying2017-05-19

Lobbying return by Ibec

Public Expenditure and Reform
Intended results

To ensure understanding of TDs in the Dublin and the Mid-East (Wicklow and Kildare) areas on the priorities of business for Ireland's development both economically and socially.::To ensure understanding of TDs in the Mid-East of the potential ambitious investment policies and…

Derived link · Matched by name with added legal form

Published name "Ibec" has no legal form. "IBEC COMPANY LIMITED BY GUARANTEE" (CRO 8706) is the only CRO company with that name plus any legal form (Limited, DAC, UC, CLG, PLC or Teoranta). Confirm against the CRO record before relying on it.

Register of Lobbying2017-05-19

Lobbying return by Disability Federation of Ireland

Justice and Equality
Intended results

To maximise compliance with the UN CRPD.

Derived link · Matched by exact company name

Published name "Disability Federation of Ireland" equals CRO name "DISABILITY FEDERATION OF IRELAND" (CRO 140948) after normalising legal forms such as Ltd = Limited. No other CRO company has this name. Names can be shared, so compare the address and dates on the CRO record.

Register of Lobbying2017-05-19

Lobbying return by Dublin Chamber of Commerce

Local Government
Intended results

Ensure joined up thinking across the local authorities of County Dublin and Greater Dublin Area.::Create policies that make Dublin more attractive for residents, commuters, visitors and employers as it competes with other international city regions.::Development of a long-term…

Register of Lobbying2017-05-18

Lobbying return by Dublin Simon Community

Health
Intended results

awareness of intended planing application

Derived link · Matched by exact company name

Published name "Dublin Simon Community" equals CRO name "DUBLIN SIMON COMMUNITY" (CRO 32955) after normalising legal forms such as Ltd = Limited. No other CRO company has this name. Names can be shared, so compare the address and dates on the CRO record.

Register of Lobbying2017-01-20

Lobbying return by The Irish Clinical Oncology Group t/a Cancer Trials Ireland

Health
Intended results

Cancer trials should be integrated into the National Cancer Control Programme at a national policy level and promoted to all clinicians as a mainstream treatment option. Increase the number of people participation in cancer drug trials to 5% - currently at 3%..